Actively Recruiting
New Treatment Combining PT, Fludarabine, and Cyclophosphamide to Help Unrelated Cord Blood Engraft in Children With Leukemia Undergoing Haploidentical-Cord Transplant
Led by Nanfang Hospital, Southern Medical University · Updated on 2023-12-04
60
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating a new post-transplant treatment regimen combining post-transplant cyclophosphamide, fludarabine, and cyclophosphamide PTFLUCY to see if it helps unrelated cord blood engraft better in children undergoing haploidentical-cord stem cell transplantation for leukemia. This study focuses on childhood leukemia patients receiving this novel approach to improve the unpredictability of graft engraftment in this transplant setting. The treatment involves a conditioning regimen with fludarabine given from day -5 to day -3 and again on days 3 and 4, busulfan from day -6 to day -3, infusion of haploidentical peripheral blood stem cells on day 0, cyclophosphamide on days 3 and 4, and unrelated cord blood infusion on day 6. This regimen is being studied as a single-arm, multi-center trial to assess its effects on promoting cord blood engraftment. Participants will be monitored starting from day 15 post-transplant with weekly STR detection for up to one year to measure cord blood engraftment. Researchers will also follow leukemia-free survival and overall survival rates for three years after transplantation. The study involves regular evaluations to assess the effects of the treatment and monitor patient outcomes during and after the transplant process.
CONDITIONS
Brief Title
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
Research Team
Y
Yongsheng Ruan, MD
X
Xiaoqin Feng, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
